中信建投-博雅生物(300294)Continued Focus on Core Blood Products Business,Plasma Collection Volume Hits a New Record High-260325

登录忘记密码注册

>> 中信建投-博雅生物(300294)Continued Focus on Core Blood Products Business,Plasma Collection Volume Hits a New Record High-260325

上传日期：	2026/3/26	大小：	477KB
格式：	pdf 共9页	来源：	中信建投
评级：	--	作者：	--
下载权限：	此报告为加密报告

相关研报

中信建投-交通运输：Inventory ratchet effect and the intertemporal restocking wave in the oil tanker industry-260325
中信建投-中国金茂(00817.HK)2025 Annual Results Review_Marginal improvement in profitability and sustained decline in funding costs-260325
中信建投-上海银行(601229)Steady earnings growth, with an outstanding dividend profile-260325
中信建投-万物云(02602.HK)2025 full-year performance review_Core net profit shows positive growth,proactive dividend payouts reward shareholders-260325
中信建投-FinVolution(FINV.N)Overseas dual-line business strategy hedges domestic volatility,full-year performance demonstrates strong resilience-260324
中信建投-房地产：Real Estate Asset Securitization Series_Outlet industry shows operating resilience,bullish on leading operators and their REITs-260325
中信建投-微泰医疗-B(02235.HK)Earnings forecast exceeds expectations,overseas CGM volume drives strong revenue growth-260324
中信建投-万泽股份(000534)Power Generation Research Series_It takes 10 years to forge a perfect sword_gas turbine+aero engine blades are about to see a demand surge-260324
中信建投-Qfin Holdings Inc(QFIN.O)Short-term performance under pressure, risk inflection point has emerged, long-term advantages of industry leaders stand out-260324
中信建投-Futu Holdings(FUTU.O)Impressive performance with major achievements in global business strategy-260324

Copyright © 2005 - 2021 Nxny.com All Rights Reserved 备案号：蜀ICP备15031742号-1